Rethinking Letermovir Strategy Beyond Day +100 for Late CMV Prevention After Allogeneic Hematopoietic Cell Transplantation

Transplantation and Cellular Therapy · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles